Retinal disease is an aggressive and potentially deadly disease caused by abnormal cells in the retina, the tiny cells that surround our eyes and make up our vision.
It can cause visual impairment and lead to blindness and death.
To treat it, doctors usually use a powerful new technique called optoelectronic surgery (OES).
This involves inserting a small tube into the retina that stimulates a protein called retinol into the blood.
The result is an image that’s sharper and clearer than usual, and the disease goes away after just a few weeks.
But many people with retinitis pigmentosa (RPOS), which affects about 1 in 100 people, experience a worsening of the condition after a few months of treatment.
And the drug retinacin, which has been used to treat RPOS since the 1970s, doesn’t work well for those with retinal disease.
The problem is, there aren’t enough of these drugs in the market to help people who have it.
Now researchers are coming up with a new way to treat people with RPOS.
Retinacil is one of the first drugs approved by the FDA to treat the disease.
In addition to being used to help treat RPOC patients, retinaclin has been shown to help fight other types of eye cancer and has been approved by other countries for use in treating glaucoma and other eye conditions.
This is a new class of drug that targets the same protein that activates retinacholase, a protein that’s made by the retinal pigment epithelial cells that line the retina.
Because retininachal cells make up the vast majority of the eye’s retina, retinal cells in patients with RPOC can become overexpressed and become toxic to the rest of the retina (known as hyperkeratosis).
The result can be an increased risk of developing retinal and brain cancers.
So how do these drugs work?
When retinal photoreceptors are overexposed, they can become toxic, which means they’re unable to detect light or other light-sensitive cells.
This can lead to cells in surrounding tissues being activated and attacking other cells.
But retinocortin, a drug produced by a drug company called Merck, blocks that toxic process.
It blocks the protein from being activated by the receptor, thereby preventing the toxicity.
This means that, after several weeks of treatment, the retinocytes are no longer activated by that receptor, and they no longer attack other cells in other tissues.
So the drug has been given a thumbs-up by doctors who say it will help treat retinal diseases and glauco-corneal neoplasia (GCN).
Retinaclil is approved for patients over the age of 45 and can be taken for up to six months.
But the drug hasn’t been approved for use for people under the age 21, and it has been taken off the market.
So if you or anyone you know has RPOC, you might want to consider getting some retinaciocorticosteroids, which are FDA-approved drugs that can be given in doses of 10 to 100 mg daily.
They’re often given in combination with retinyl ester, a chemical compound that’s also found in retinoids.
The drugs are designed to help regulate retinal inflammation and have a short-term effect, but the long-term benefit is promising.
“Retinacels are a promising class of drugs that may help treat vision loss and other disorders caused by retinal damage,” said Dr. James Koehler, director of the University of Texas at Austin Eye Institute, in a press release.
“These drugs are well tolerated and have not been associated with any adverse effects, and their ability to slow the progression of retinotoxicity may be of benefit to patients and the broader public.”
The researchers behind the drug, from the University’s School of Medicine, said that they are hoping to make the drug available in the U.S. by 2019.
They hope to use the drug to treat patients in a variety of other diseases, including depression and schizophrenia.